The record
| Class | bioregulator |
|---|---|
| Also known as | EDP, Glu-Asp-Pro, thymic tripeptide |
| Chain length | 3 residues |
| Molecular weight | 359.33 Da |
| Half-life | - |
| Route | SC / oral (class) |
| Studied for | - |
| Research use | - |
| What has been shown | - |
| How it works | Khavinson thymic tripeptide bioregulator; studied for T-lymphocyte proliferation and immune function normalisation. |
| Patent status | - |
| Regulatory status | - |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Cancer immunotherapy adjuvant (illness, 30%)
- COVID-19 (illness, 30%)
- Hepatitis B/C treatment (illness, 30%)
- Sepsis treatment (illness, 30%)
- Vaccine adjuvant (illness, 30%)
- Frequent infections (symptom, 50%)